Literature DB >> 3886795

Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections.

L Hagberg, D E Briles, C S Edén.   

Abstract

Past studies have suggested a linkage between susceptibility to Salmonella typhimurium infection and the Lpsd genotype in C3H mice. Recently, this linkage was questioned by the finding that C3HeB/FeJ mice (Lpsn,Lpsn) were highly susceptible to systemic S. typhimurium infection. The present study shows a marked difference between C3H/HeJ and C3HeB/FeJ in their susceptibility to Gram-negative urinary tract infection. The number of E. coli and S. typhimurium recovered from the kidneys 24 hr after infection was 70 to 100 times higher in C3H/HeJ than in C3HeB/FeJ or C3H/HeN mice. Subsequently, in C3HeB/FeJ mice S. typhimurium multiplied to the level of C3H/HeJ mice, resulting in a shorter mean survival time of C3H/HeJ and C3HeB/FeJ compared with C3H/HeN mice. In contrast, E. coli remained localized to the urinary tract of C3H/HeJ mice but were eliminated from C3HeB/FeJ and C3H/HeN mice. Thus, experimental E. coli urinary tract infection appears to provide a method to differentiate the genetic defects of C3H/HeJ and C3HeB/FeJ mice. The results support an influence of the Lpsd genotype on clearance of Gram-negative bacteria from the kidneys of C3H mice.

Entities:  

Mesh:

Year:  1985        PMID: 3886795

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Bacterial motility is a colonization factor in experimental urinary tract infection.

Authors:  A Siitonen; M Nurminen
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

Review 2.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

3.  Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria.

Authors:  Jill R Schurr; Erana Young; Pat Byrne; Chad Steele; Judd E Shellito; Jay K Kolls
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

Review 4.  Genetics of innate immunity and UTI susceptibility.

Authors:  Bryndís Ragnarsdóttir; Nataliya Lutay; Jenny Grönberg-Hernandez; Bela Köves; Catharina Svanborg
Journal:  Nat Rev Urol       Date:  2011-07-12       Impact factor: 14.432

5.  Comparison of asymptomatic bacteriuria Escherichia coli isolates from healthy individuals versus those from hospital patients shows that long-term bladder colonization selects for attenuated virulence phenotypes.

Authors:  Ellaine Salvador; Florian Wagenlehner; Christian-Daniel Köhler; Alexander Mellmann; Jörg Hacker; Catharina Svanborg; Ulrich Dobrindt
Journal:  Infect Immun       Date:  2011-11-21       Impact factor: 3.441

Review 6.  Genetic risk for recurrent urinary tract infections in humans: a systematic review.

Authors:  M Zaffanello; G Malerba; L Cataldi; F Antoniazzi; M Franchini; E Monti; V Fanos
Journal:  J Biomed Biotechnol       Date:  2010-03-30

7.  Bacterial virulence versus host resistance in the urinary tracts of mice.

Authors:  C Svanborg-Edén; L Hagberg; R Hull; S Hull; K E Magnusson; L Ohman
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

8.  Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2.

Authors:  Seung Hyun Han; Je Hak Kim; Michael Martin; Suzanne M Michalek; Moon H Nahm
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

Review 9.  Host parasite interaction in urinary tract infection.

Authors:  C Svanborg-Edén; P de Man; U Jodal; H Linder; H Lomberg
Journal:  Pediatr Nephrol       Date:  1987-10       Impact factor: 3.714

10.  Role of lipopolysaccharide in induction of Ia expression during infection with gram-negative bacteria.

Authors:  N E Marshall; H K Ziegler
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.